Lyell Immunopharma: High‑Tech Ambitions vs. Financial Instability and VolatilityLyell Immunopharma’s lofty cellular‑therapy claims clash with a volatile, loss‑driven stock—why investors should weigh risk over hype.LYELL IMMUNOPHARMA INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 18/11/2026, 18:06 2 minutes to read